Innovative Synthesis of Diltiazem/Clentiazem Analogs by Magtanong, Emelyn
Journal of Interdisciplinary Undergraduate Research
Volume 8 Journal of Interdisciplinary Undergraduate
Research Article 4
2016
Innovative Synthesis of Diltiazem/Clentiazem
Analogs
Emelyn Magtanong
emelynm@southern.edu
Follow this and additional works at: https://knowledge.e.southern.edu/jiur
Part of the Chemicals and Drugs Commons, and the Chemistry Commons
This Article is brought to you for free and open access by the Peer Reviewed Journals at KnowledgeExchange@Southern. It has been accepted for
inclusion in Journal of Interdisciplinary Undergraduate Research by an authorized editor of KnowledgeExchange@Southern. For more information,
please contact jspears@southern.edu.
Recommended Citation
Magtanong, Emelyn (2016) "Innovative Synthesis of Diltiazem/Clentiazem Analogs," Journal of Interdisciplinary Undergraduate
Research: Vol. 8 , Article 4.
Available at: https://knowledge.e.southern.edu/jiur/vol8/iss1/4
 
 
 
Innovative Synthesis of 
Diltiazem/Clentiazem Analogs 
 
Emelyn Magtanong 
Southern Adventist University 
Collegedale, TN 37315 
 
 
  
 
  
Research Advisor: Dr. Herman Odens 
1 
 
Abstract  
Cardiovascular disease defines disorders of the heart and blood vessels, and is the 
number one cause of death in America. Diltiazem and clentiazem are common calcium channel 
blockers incorporated into drugs used to treat various cardiovascular diseases. Methods to 
synthesize 5-[2-(dimethylamino)ethyl]-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one, 
an analog of the core of diltiazem and clentiazem, using cost-efficient starting materials allows 
for affordable treatment and increased availability to affected individuals. N-(N,N-
dimethylethanamine)-4-aminophenol  can be oxidized to form  a quineoneimine, which can be 
further reacted with 3-mercaptopropionic acid via Michael addition. Subsequent addition of  a 
coupling reagent, N,N'-dicyclocarbodiimide (DCC),1  produces 5-[2-(dimethylamino)ethyl]-8-
hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one, analogous to the core structure of 
diltiazem and clentiazem. Final compounds can then be subjected to biological testing to 
determine successful inhibition of calcium channels leading to vasodilation.  This four step total 
synthesis approach provides an innovative synthesis methodology. 
2 
 
Introduction 
 Cardiovascular disease is the leading cause of death in America.1,2  This disease can 
affect people of all ages, sex, and color, and is often triggered by stress, unhealthy habits, 
and/or genetics.  Cardiovascular disease is a simple term used to describe various disorders of 
the heart, including those involved with build-up of plaque in arteries, reducing blood flow, and 
increasing the risk of a heart attack or stroke.  According to Centers for Disease Control and 
Prevention, about 600,000 people die of heart disease in the United States every year.3,4  Of the 
different types of cardiovascular diseases, coronary heart disease is the most common.  Lack of 
knowledge and late detection of symptoms have led to death rate increases per year.   
Researchers have put forth effort to synthesize drugs to treat various cardiovascular 
diseases.  Dongming Cai and his team of researchers have found a correlation between 
benzothiazepines, Ca2+ channels, and heart disease.5  According to Cai, members of 
benzothiazepines are useful in treating disorders such as: angina, hypertension, and cardiac 
arrhythmias.  Benzothiazepines act as a calcium channel blocker, relaxing blood vessels, 
allowing blood to flow regularly.  Derivatives of benzothiazepine, diltiazem and clentiazem, are 
known calcium channel blockers incorporated into drugs used to treat cardiovascular diseases.   
 
 
 
 
Figure 1.  Structures of Diltiazem and Clentiazem 
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In this experiment, we will be synthesizing an analog of diltiazem and clentiazem, 
following the work of Alan Katritzky et al.  on the synthesis of benzothiazepinones and 
benzothiazinones.6  However, a different starting material will be used, N-(N,N-
dimethylethanamine)-4-aminophenol, obtained from a previous research experiment 
performed by David Chang.   
Route 1 
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The goal of this project is to design an alternative method to synthesize 5-[2-
(dimethylamino)ethyl]-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one, an analog of 
the core of diltiazem and clentiazem, using cost-efficient starting materials.  The compound will 
be synthesized by oxidizing N-(N,N-dimethylethanamine)-4-aminophenol with an appropriate 
oxidizing agent, and adding 3-mercaptopropionic acid via Michael addition.  Afterwards, a 
coupler will be introduced to synthesize our desired product.  Biological testing will then be 
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performed on the compound to evaluate its reactivity in the human body and its success as a 
calcium channel blocker. 
Methods 
 Experimental procedures were performed at Southern Adventist University Chemistry 
Department using standard laboratory glassware, and materials and chemicals manufactured 
by Acros, Alfa Aesar, AnalTech, Chemglass, and Fisher Scientific.  Each reaction was carried out 
using Chemglass Pie-Blocks (CG-1991-P), Wilmad LabGlass Rotovapor (WG-EV311), RE11 Buchi 
Rotavapor (1024648), Chemglass Optimag Magnetic Hot Plate Stirrers (CG-1994), HP/Agilent 
1100 MSD LC/MS, and a Spectroline Short Wave UV lamp (EF-140C, 254nm).   
Reaction 1: Synthesis of Compound 2 
 Route 1. A solution was prepared by dissolving N-(N,N-dimethylethanamine)-4-
aminophenol (0.052 g, 0.277 mmol) in acetonitrile (0.454 mL) and water (0.230 mL) in a 
reaction vial.  While the solution was stirring, bis(trifluoroacetoxy)iodobenzene (PIFA) (0.2393, 
0.277 mmol) was added.  The reaction was run at 25˚C for one hour, and thin-layer 
chromatography (TLC) was performed to monitor formation of product from starting material.  
The reaction was left stirring for seven days and further analyzed via TLC.   
 Route 2. A mixture was prepared by dissolving N-(N,N-dimethylethanamine)-4-
aminophenol (0.0503 g, 0.277 mmol) in hexane (0.9 mL) and three drops of methanol. While 
the mixture was stirring, NaOCl was added (6% conc., 0.400 mL, 0.0277 mmol). The reaction vial 
was covered in foil and left stirring at 25˚C for one hour. The reaction was monitored by TLC 
and analyzed using liquid chromatography mass spectrometry (LCMS).   The vial was stored in a 
refrigerator at 4˚C for one week. 
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Reaction 2: Synthesis of compound 3. 
 Route 1.   After compound 2 was synthesized, 3-mercaptopropionic acid (0.020 mL, 
0.277 mmol) was injected into the reaction vial, and left running for seven days.   The solution 
was monitored by TLC, and analyzed using LCMS.   
 Route 2.   After compound 2 was synthesized, 3-mercaptopropionic acid (0.025 mL, 
0.277 mmol) was injected into the reaction vial, and left stirring at 25˚C for one hour. The 
reaction was monitored by TLC, and stored in a refrigerator at 4˚C for one week. 
Reaction 3: Synthesis of 5-[2-(dimethylamino)ethyl]-8-hydroxy-2,3,4,5-tetrahydro-1,5-
benzothiazepin-4-one (compound 4) 
Route 1. Sodium sulfate (3.628 g) was added into the vial to remove excess water. The 
solution was filtered using a 50 mL filtering flask, followed by subsequent washes with 
acetonitrile.  The filtrate was transferred back into the reaction vial, and dicyclocarbodiimide 
(DCC) (0.577 g, 0.277 mmol) was added.  Reaction was left stirring for one week at 25˚C.   The 
reaction was monitored by TLC and further analyzed by LCMS.   Once reaction reached 
completion, the solvent was evaporated under reduced pressure to achieve a dark brown solid. 
 Purification.  The crude product was dissolved in ethyl acetate and dichloromethane and 
purified using column chromatography.  A 40:1 ratio of silica gel to crude mass was calculated 
for the column.  Silica gel was mixed with ethyl acetate and was poured into the column.  After 
washing the column three times with ethyl acetate, the dissolved crude product was added.  
The solvent system used was a 9.7:0.3:0.03 ratio of ethyl acetate: methanol: acetic acid.  The 
column was subject to pressurized nitrogen gas; twenty-five 20 mL fractions were obtained.  
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Fractions containing product were evaporated under reduced pressure to obtain a maroon 
solid. 
A second column chromatography run was performed with the same solvent system, 
using a dry pack loading method prepared with crude product obtained from the previous 
chromatography run.   Next, a 2:1 ratio of silica gel to crude mass was calculated.   The 
calculated amount of silica gel was added to the crude product, mixed with the least polar 
solvent.   The solvent was evaporated, leaving a dry powder to be added into the column.   
Twenty-five 20 mL fractions were collected and analyzed via TLC.   Selected fractions containing 
product were evaporated under reduced pressure to obtain a dark brown solid. The solid was 
further analyzed using LCMS and proton nuclear magnetic resonance (1H NMR) spectroscopy. 
Route 2. Sodium sulfate (0.5073 g) was added to remove excess water, and the solution 
was filtered using a 50 mL filtering flask, followed by subsequent washes with acetonitrile. 
Filtrate was transferred into a new reaction vial and solvent was evaporated under reduced 
pressure to obtain a dark yellow solid. The solid was dissolved in 1 mL tetrahydrofuran (THF) 
followed by the addition of DCC (0.583 g, 0.277 mmol). The reaction was left stirring for one 
week at 25˚C, while being monitored via TLC. TLC analysis showed the presence of a new spot, 
believing to be compound 5. Solvent was again removed under reduced pressure to obtain a 
dark yellow solid. 
Purification. Column chromatography was performed using a solvent system composed 
of hexane and ethyl acetate in a 1:1 ratio. A 20:1 ratio of silica gel to crude mass was calculated 
for the column.  Silica gel was poured into the column followed by the addition of hexane.  
Next, a 2:1 ratio of silica gel to crude mass was calculated. The calculated amount of silica gel 
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Figure 3.  TLC analysis of compound 2 synthesized via 
Route 1 (A) and Route 2 (B). 
was added to the crude product and mixed with the least polar solvent.   The solvent was 
evaporated, leaving a dry powder to be added into the column.  Thirty 8 mL fractions were 
collected and analyzed via TLC.   Selected fractions containing product were evaporated under 
reduced pressure to obtain a white solid. The solid was further analyzed using proton nuclear 
magnetic resonance (1H NMR) spectroscopy. 
Results 
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Figure 4. LCMS results for compound 2 synthesized using NaOCl 
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Reaction 2 
 
 
 
 
 
 
 
 
 
Reaction 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  LCMS results for compound 3 (Route 1) under 
single ion mode (SIM). 
 
Figure 5. TLC results of compound 3 (Route 2) 
Figure 7. LCMS results for compound 4 (Route 1) after purification on scan mode. 
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Figure 8. 1H NMR results of compound 4 (Route 1) after purification. 
Figure 9. 1H NMR results of compound 4 (Route 2) after purification 
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Discussion 
Various approaches were made to promote reaction completion.  For reaction 1, under 
route 1 and route 2, reaction vials were covered in foil to protect the oxidized product from 
light, and was kept at 25˚C to prevent heat degradation.   
Route 1 
As can be seen from Figure 3A, a new spot with an Rf value of 0.583 appeared during 
TLC, suggesting the oxidation reaction had occurred. TLC results were unclear for reaction 2, 
but when performing LCMS on single-ion mode (SIM), data showed a signal at the molecular 
weight of our deprotonated product (Figure 6).   This gave a strong indication that the reaction 
proceeded to completion. 
 
 
  
Figure 10. Predicted 1H NMR results of compound 4 
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Figure 11. HNMR prediction of possible compound ENM7-32-IA (Route 1) 
Figure 12. Proposed mechanism for possible products formed in reaction 3 following Route 1 
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Before beginning reaction 3, sodium sulfate was introduced to compound 3 to remove 
water introduced from reaction 1 that may interfere with DCC.   During filtration, small 
amounts of product may have been lost, decreasing our overall yield.   In Figure 7, LCMS 
analysis on scan mode of our newly purified product detected other compounds present in our 
final reaction.  A peak at the target product molecular weight (266.354) can be seen among 
various peaks, most likely belonging to impurities. 1HNMR spectroscopy was performed to 
confirm the synthesis of compound 4, followed by comparison to our 1HNMR prediction in 
Figure 10.  From the data presented in Figure 8, peaks at 6.7 – 7.0 ppm were absent, and peaks 
at 1.0-2.2 ppm were detected, suggesting a different compound was synthesized. We 
hypothesize that a reaction occurred between DCC and 3-mercaptopropionic acid forming a 
cyclized structure of 3-mercaptopropionic acid attached to DCC (compound 5). Compound 5 
can be further reacted with excess 3-mercaptopropionic acid and undergo a hydride shift to 
produce compound 6. The predicted 1HNMR results in Figure 8 reveals peaks corresponding to 
hydrogens surrounding cyclohexane, providing an explanation for signals detected at 1.0-2.2 
ppm in Figure 8.  A proposed mechanism for the synthesis of reaction is shown in Figure 12.  
 Route 2. 
 In Figure 3B, the disappearance of a spot in the product lane (Rf = 0.337) suggests that 
the oxidation using NaOCl was successful during reaction 1. LCMS analysis was also performed 
to confirm our prediction; results show a signal at the expected deprotonated mass (177.0), 
shown in Figure 4. After completing reaction 2, TLC analysis gave a positive indication that the 
thionucleophile (3-mercaptopropionic acid) reacted with the quinoneimine (compound 2), 
showing the appearance of a new spot with an Rf of 0.50 (Figure 5).  
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Before proceeding with reaction 3, sodium sulfate was added to compound 3 to remove 
additional water incorporated with NaOCl in reaction 1 that may interfere with DCC.   During 
filtration, small amounts of product may have been lost, decreasing our overall yield. After a 
crude solid was obtained, there was difficulty in dissolving solid in a solvent such as 
dichloromethane (DCM); THF was chosen as the most suitable solvent. Insoluble solids found in 
the solution may have been remaining sodium ions from sodium sulfate.  1HNMR spectroscopy 
was performed to confirm the synthesis of compound 4, and was compared to our 1HNMR 
prediction in Figure 10.  From the data presented in Figure 9, peaks at 6.5 – 7.5 ppm were 
present, suggesting the presence of a chromophore. However, peaks at 1.0-2.2 ppm, 5.5-6.0 
ppm, and 8.0-10.0 ppm were detected, suggesting a different compound was synthesized. 
Possible structures synthesized from this reaction are yet to be determined. 
  
Conclusion 
 According to Figure 6 and 7, the target product was not synthesized in this experiment, 
therefore determination of effective oxidizing and coupling agents is essential for the 
production of the target compound. Future research can be performed using a combination of 
various oxidizing methods and different coupling agents in an attempt to synthesize and isolate 
5-[2-(dimethylamino)ethyl]-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one (5). 
Possible methods include isolating compound 2 to ensure successful synthesis before 
proceeding with subsequent steps. A good reaction procedure for adding the thionucleophile to 
the quinoneimine must be established before continuing on to produce compound 5. Once 
compound 5 is successfully synthesized, reaction with chiral thiol nucleophiles can be 
performed to develop a library of chiral 1,5-benzothiazepinones and complete the synthesis of 
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diltiazem and clentiazem analogs. Biological testing can then be done to further assess their 
usefulness in treating cardiovascular diseases. 
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